Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update

Atyr PHARMA INC (NASDAQ:ATYR) was the recipient of a large increase in short interest in November. As of November 15th, there was short interest totalling 2,110,000 shares, an increase of 27.1% from the October 31st total of 1,660,000 shares. Based on an average trading volume of 858,600 shares, the short-interest ratio is presently 2.5 days. Currently, 2.6% of the company’s stock are short sold.

Atyr PHARMA Price Performance

Shares of NASDAQ:ATYR traded up $0.09 during midday trading on Friday, hitting $3.53. The company had a trading volume of 543,548 shares, compared to its average volume of 583,698. Atyr PHARMA has a twelve month low of $1.14 and a twelve month high of $3.80. The stock has a market capitalization of $296.31 million, a PE ratio of -3.76 and a beta of 1.10. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average is $2.75.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). As a group, sell-side analysts forecast that Atyr PHARMA will post -0.89 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ATYR. Wells Fargo & Company initiated coverage on Atyr PHARMA in a research report on Friday, October 4th. They set an “overweight” rating and a $17.00 target price on the stock. Jefferies Financial Group started coverage on Atyr PHARMA in a research note on Thursday, September 5th. They issued a “buy” rating and a $9.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Tuesday, October 29th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Atyr PHARMA in a report on Wednesday, August 14th.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.